Class benefits of AT1 antagonists in Type 2 diabetes with nephropathy

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.3, Iss.5, 2002-05, pp. : 625-628

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Radiation Nephropathy with ACE Inhibitors and AII Type-1 and Type-2 Receptor Antagonists

Current Pharmaceutical Design, Vol. 13, Iss. 13, 2007-05 ,pp. : 1317-1325

Bentham Science Publishers

Access to resources Recommend Favorite

Glucagon antagonists for the treatment of Type 2 diabetes

By Connell R.D.

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 6, 1999-06 ,pp. : 701-709

Informa Healthcare

Access to resources Recommend Favorite

Benefits of intensive therapy in type 1 diabetes maintained

Inpharma, Vol. 1, Iss. 1225, 2000-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Muraglitazar: multiple benefits in type 2 diabetes

Inpharma, Vol. 1, Iss. 1496, 2005-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

Renin-Angiotensin-Aldosterone System Antagonists and the Prevention of Type 2 Diabetes Mellitus

Current Pharmaceutical Design, Vol. 18, Iss. 7, 2012-03 ,pp. : 958-962

Bentham Science Publishers

Access to resources Recommend Favorite